Johnson & Johnson (JNJ)
| Market Cap | 632.39B +56.5% |
| Revenue (ttm) | 97.93B +8.1% |
| Net Income | 21.04B -7.2% |
| EPS | 8.63 -7.7% |
| Shares Out | 2.41B |
| PE Ratio | 30.05 |
| Forward PE | 21.36 |
| Dividend | $5.36 (2.04%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 1,435,864 |
| Open | 261.43 |
| Previous Close | 259.27 |
| Day's Range | 259.61 - 262.95 |
| 52-Week Range | 164.23 - 269.43 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 270.59 (+3.0%) |
| Earnings Date | Jul 15, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $270.59, which is an increase of 3.00% from the latest price.
News
Johnson & Johnson’s multiple myeloma therapy shows efficacy in Phase 3 trial
Johnson & Johnson announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating Tecvayli – teclistamab-cqyv – + Talvey – talquetamab-tgvs -, a BCMA and GP...
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluat...
US judge casts doubt on 69,000 cases alleging J&J talc caused cancer
A federal judge cast doubt on Wednesday on claims by approximately 69,000 people alleging that Johnson & Johnson's baby powder and other talc products caused ovarian cancer, saying plaintiffs must pr...
Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon
Shares in medical group Johnson & Johnson ($JNJ) were healthier today after it received the green light to begin the “next era” of robotic surgery. Robotic Operating Tables The company…
Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved
The approval opens a new market for the healthcare company.
Johnson & Johnson's robotic surgery device gets US FDA marketing authorization
Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to ...
Johnson & Johnson receives FDA Marketing Authorization in U.S. for OTTAVA
Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has granted De Novo authorization for the OTTAVA Robotic Surgical System. The system received marketing authorization for m...
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the ...
3 ‘Strong Buy’ Dividend Aristocrat Stocks for Steady Cash Flow, 7/21/26
Investors looking for steady cash payments can bank on NextEra ($NEE), Coca-Cola ($KO), and Johnson & Johnson ($JNJ). Top analysts covering these stocks say these dividend aristocrats are a Strong…
Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter
As previously reported, Freedom Broker analyst Ilya Zubkov upgraded Johnson & Johnson to Buy from Hold with a price target of $280, up from $230, after “a strong quarterly performance”…
Johnson & Johnson upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded Johnson & Johnson to Buy from Hold with a $280 price target
Johnson & Johnson price target raised to $305 from $265 at Scotiabank
Scotiabank raised the firm’s price target on Johnson & Johnson to $305 from $265 and keeps an Outperform rating on the shares. The firm is raising its price target following…
Johnson & Johnson price target raised to $265 from $258 at Raymond James
Raymond James raised the firm’s price target on Johnson & Johnson to $265 from $258 and keeps an Outperform rating on the shares. Continued momentum demonstrated in Q2 gives the…
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare profe...
DePuy Synthes Acquires Expanding Innovations™
RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable...
Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Johnson & Johnson to $282 from $275 and keeps a Buy rating on the shares after its Q2 results. The overarching theme…
Johnson & Johnson price target raised to $270 from $260 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Johnson & Johnson to $270 from $260 and keeps a Neutral rating on the shares.
Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $294 from $284 and keeps an Overweight rating on the shares after the company posted…
Johnson & Johnson price target raised to $272 from $263 at Wells Fargo
Wells Fargo raised the firm’s price target on Johnson & Johnson to $272 from $263 and keeps an Overweight rating on the shares. The firm notes that cardio was unexpectedly…
Johnson & Johnson price target raised to $260 from $250 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Johnson & Johnson to $260 from $250 and keeps a Hold rating on the shares. The company delivered “solid” Q2…
J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue
The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a tab...
Johnson & Johnson: Expiration of ACA subsidies won’t impact procedure demand
Does not expect expiration of Affordable Care Act subsidies to materially impact demand for MedTech and procedures.
Johnson & Johnson Stock (JNJ) Falls despite Q2 Beat, Higher Sales Forecast for 2026
Shares in Johnson & Johnson ($JNJ) dropped about 3% early Wednesday. This came even though the U.S. pharma giant surpassed Wall Street’s sales and profit estimates for its second quarter.
Johnson & Johnson says three of four business units accelerated through Q2
Says “confidently addressing” the fourth business unit. Says procedure volumes stable, not seeing evidence of a broad based slowdown in demand.